In situ probe gel and preparation method and administration method thereof
Preparation of in-situ probe gels by hydrogel materials based on hyaluronic acid-coupled dopamine, solving the non-specific attachment and air diffusion problems of probe administration during surgery, and achieving safe and convenient probe administration and real-time fluorescence Imaging.
Patent Information
- Application Number
- CN202211721387.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-30
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-12-30
AI Technical Summary
When using fluorescence imaging technology during surgery, existing spray administration methods lead to nonspecific attachment of probes and air diffusion, causing side effects and difficulty in cleaning, lacking convenient in-situ administration methods.
In situ probe gel is prepared using hydrogel materials based on hyaluronic acid coupled dopamine. A uniform solution is formed by sonication and lyophilization. The probe and sodium periodate are added to prepare ductility and adhesion. The gel is directly applied to the area to be observed and removed with filter paper.
It realizes safe and convenient drug delivery of probes, avoids side effects caused by non-specific attachment and air diffusion, and ensures the accuracy of real-time fluorescence imaging and the convenience of cleaning intraoperatively.
Smart Images

Figure CN115998906B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of probe gel, and in particular to an in-situ probe gel and a preparation method and a drug administration method thereof. Background Art
[0002] Fluorescence imaging has the advantages of high resolution, ease of use, low price, and real-time monitoring. Therefore, its application in biological monitoring and disease diagnosis has received more and more attention. Among them, the application of fluorescence imaging in guiding surgical treatment is an important development direction. To this end, it is necessary to develop a fluorescence imaging system that can achieve real-time imaging during surgery. In the field of fluorescence imaging, in addition to the development of specific probes, safe, convenient, and efficient probe administration methods are also research focuses. In recent years, related studies have used in situ spraying to perform local administration of probes, thereby achieving rapid intraoperative fluorescence imaging.
[0003] However, the spray administration method during surgery can lead to non-specific adhesion of the probe and diffusion of the probe in the air, and the probe can be ingested by the human body through the nasal cavity, causing side effects and making postoperative cleanup difficult. Therefore, the development of a more reasonable and convenient in situ probe administration method or carrier is of great significance for intraoperative fluorescence imaging. Summary of the invention
[0004] The object of the present invention is to provide an in situ probe gel, which is a hydrogel material based on hyaluronic acid (HA) coupled with dopamine (DA), can be used to carry and slowly release probe molecules, and has good ductility and adhesion.
[0005] Another object of the present invention is to provide a method for preparing an in-situ probe gel, which is simple and has controllable parameters and is suitable for industrial large-scale production.
[0006] The third object of the present invention is to provide a probe administration method, which can achieve in situ probe administration during surgery by directly applying the in situ probe gel to the part to be observed, avoiding side effects caused by non-specific adhesion and diffusion of the probe into the air leading to human ingestion.
[0007] The present invention solves the technical problem by adopting the following technical solutions.
[0008] The present invention provides a method for preparing an in-situ probe gel, comprising the following steps:
[0009] S1. Add hyaluronic acid powder into deionized water and perform ultrasonic treatment to obtain a uniform solution;
[0010] S2, adding dopamine to the homogeneous solution, stirring at room temperature in the dark for 22 to 26 hours, centrifuging, and freeze-drying to obtain hyaluronic acid-dopamine (HA-DA);
[0011] S3. Dissolve the hyaluronic acid-dopamine in a PBS solution, perform ultrasonic treatment and stir, add the probe PBS solution and mix well, then add the sodium periodate PBS solution and mix well, and stand at room temperature in the dark for 1.5 to 2.5 hours to obtain an in situ probe gel.
[0012] The invention provides an in-situ probe gel, which is prepared according to the preparation method.
[0013] The present invention provides a probe administration method, using the in situ probe gel, comprising the following steps:
[0014] After the in-situ probe gel is applied to the part to be observed for 8 to 12 minutes, the in-situ probe gel is removed by adsorption using filter paper, and then fluorescence imaging of the part to be observed can be performed.
[0015] The beneficial effects of the in situ probe gel and its preparation method and administration method of the embodiments of the present invention are:
[0016] The present invention designs an in-situ probe gel based on hyaluronic acid coupled dopamine hydrogel material, which can be used to carry and slowly release probe molecules and has good ductility and adhesion. The in-situ probe gel is used to directly apply in-situ to the part to be observed during surgery, and then the gel is adsorbed and removed by filter paper to observe the local lesion. The use of the in-situ probe gel for probe administration can avoid the side effects caused by the non-specific adhesion and diffusion of the probe into the air when spray administration is used, resulting in human ingestion. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0018] Figure 1 This is a flow chart of the administration of the in situ probe gel according to an embodiment of the present invention;
[0019] Figure 2 is the H NMR spectrum of HA-DA of Example 1 of the present invention;
[0020] Figure 3 This is a morphology diagram of the in-situ probe gel of Example 1 of the present invention;
[0021] Figure 4 Schematic diagram of the viscoelasticity of the in situ probe gel of Example 1 of the present invention;
[0022] Figure 5A This is a SEM image of the in-situ probe gel of Example 1 of the present invention;
[0023] Figure 5B This is an AFM image of the in-situ probe gel of Example 1 of the present invention;
[0024] Figure 6 This is a fluorescence imaging diagram of the in situ probe gel after delivering the probe molecule according to Example 1 of the present invention;
[0025] Figure 7 This is a fluorescence imaging image of the in situ probe gel of Example 1 of the present invention;
[0026] Figure 8 This is a fluorescence imaging image of the in situ probe gel of Example 2 of the present invention. DETAILED DESCRIPTION
[0027] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0028] The in situ probe gel and its preparation method and administration method according to the embodiment of the present invention are described in detail below.
[0029] The present invention provides a method for preparing an in-situ probe gel, comprising the following steps:
[0030] S1. Add hyaluronic acid powder into deionized water and perform ultrasonic treatment to obtain a uniform solution.
[0031] Furthermore, in a preferred embodiment of the present invention, the mass volume ratio of the hyaluronic acid powder to deionized water is 4.8-5.2:1 (mg / mL).
[0032] Furthermore, in a preferred embodiment of the present invention, the mass ratio of the hyaluronic acid powder to the dopamine is 9.5-10.5:1.
[0033] S2. After adding dopamine to the uniform solution, stirring was carried out at room temperature in the dark for 22 to 26 hours, centrifuging and freeze-drying to obtain hyaluronic acid-dopamine.
[0034] Furthermore, in a preferred embodiment of the present invention, the number of centrifugation is 4 to 6 times. Preferably, a 50 mL ultrafiltration centrifuge tube (3Kd) is used for centrifugation, the volume is supplemented with deionized water, and the centrifugation is repeated 5 times to remove unreacted dopamine to obtain a concentrated solution. The concentrated solution is then freeze-dried to obtain hyaluronic acid-dopamine.
[0035] S3. Dissolve the hyaluronic acid-dopamine in a PBS solution, ultrasonically treat and stir, add the probe PBS solution and mix well, then add the sodium periodate PBS solution and shake and mix well, and stand at room temperature in the dark for 1.5 to 2.5 hours to obtain an in situ probe gel.
[0036] Furthermore, in a preferred embodiment of the present invention, the mass volume ratio of the hyaluronic acid-dopamine to the PBS solution is 23-27:1 (mg / mL).
[0037] Furthermore, in a preferred embodiment of the present invention, the pH value of the PBS solution is 7.35-7.45.
[0038] Further, in a preferred embodiment of the present invention, the mass volume ratio of the hyaluronic acid-dopamine and the PBS solution of the probe is 95-105:1 (mg / mL), the PBS solution of the probe also includes dimethyl sulfoxide, and in the PBS solution of the probe, the concentration of the probe is 48-52 μmol / L, and the mass percentage of the dimethyl sulfoxide is 4.5-5.5%. Preferably, in the PBS solution of the probe, the concentration of the probe is 50 μmol / L, and the mass percentage of dimethyl sulfoxide is 5%.
[0039] Further, in a preferred embodiment of the present invention, the mass volume ratio of the hyaluronic acid-dopamine to the potassium periodate PBS solution is 1:2.3-2.7 (mg / mL), and the molar concentration of potassium periodate in the potassium periodate PBS solution is 4-4.1 mol / L. Preferably, the molar concentration of potassium periodate in the potassium periodate PBS solution is 4.05 mol / L.
[0040] The present invention provides an in-situ probe gel, which is prepared according to the preparation method. The present invention prepares an in-situ probe gel based on hyaluronic acid-coupled dopamine hydrogel material, and the gel is loose and porous inside, which is conducive to the accumulation and sustained release of the probe solution. In addition, the in-situ probe gel also has good ductility and adhesion.
[0041] Reference Figure 1 As shown, the present invention provides a probe administration method, using the in situ probe gel, comprising the following steps:
[0042] After applying the in situ probe gel to the part to be observed for 8 to 12 minutes, remove the in situ probe gel by adsorption with filter paper, and then perform fluorescent imaging of the part to be observed. Preferably, the application time is 10 minutes. The in situ probe gel of the present invention can be used to directly apply in situ to the part to be observed during surgery, and the local lesions can be observed after the gel is removed by adsorption with filter paper. For example, in endarterectomy for the treatment of atherosclerotic plaques, the size and location of plaques on the blood vessel wall can be easily determined in this way. The use of the in situ probe gel for probe administration can avoid the side effects of human ingestion caused by the non-specific adhesion and diffusion of the probe into the air when spray administration is used.
[0043] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0044] Example 1
[0045] The in situ probe gel provided in this embodiment is prepared according to the following method:
[0046] (1) Take 100 mg of hyaluronic acid powder and add it to 20 mL of deionized water, dissolve it with ultrasound assistance, and form a 20 mL uniform solution. Then add 10 mg of dopamine and stir it at room temperature in the dark for 24 hours. Use a 50 mL ultrafiltration centrifuge tube (3Kd), make up the volume with deionized water, repeat centrifugation 5 times to remove unreacted dopamine, obtain a concentrate, and then freeze-dry to obtain HA-DA.
[0047] (2) Dissolve 100 mg HA-DA in 4 mL PBS solution (pH = 7.4), sonicate and stir to fully dissolve, then add 1 mL lipid droplet / ONOO - The PBS solution (50 μM, DMSO content: 5%) of the dual-response fluorescent probe (CNP2-B) was shaken and mixed, and then 250 uL of 4.05 mol / L sodium periodate PBS solution was added. After shaking and mixing, it was allowed to stand at room temperature in the dark for 2 hours to obtain the in situ probe gel.
[0048] Wherein, the preparation method of CNP2-B is:
[0049] (2.1) Compound 4-fluoro-2-hydroxybenzaldehyde (100 mg, 0.713 mmol) and K2CO3 (246.59 mg, 1.78 mmol) were added to 20 mL of acetonitrile and stirred for 5 minutes, followed by the addition of compound 4-(bromomethyl)phenylboronic acid pinacol ester (211.97 mg, 0.73 mmol) and stirred for 24 hours overnight. The solvent was then removed under reduced pressure. The product was purified using a silica gel column (DCM / MeOH=100:1) to obtain a light yellow solid, i.e., the intermediate CN-1.
[0050] (2.2) Compound CN-1 (100.0 mg, 0.280 mmol) and 0.5 mL of Et3N were added to a mixed solution of EtOH / DCM (10 mL:10 mL), stirred at room temperature for 5 minutes, and then benzothiazole-2-acetonitrile (48.91 mg, 0.280 mmol) was added to the reaction solution, and reacted at room temperature for 2 h. After removing the solvent under reduced pressure, the product was suspended with 20 mL of EA and then filtered to obtain an orange solid, i.e., the intermediate product CN-2.
[0051] (2.3) Compound CN-2 (100.0 mg, 0.195 mmol) and 0.5 mL of 3,5-dimethylpiperidine were added to 10 mL of DMF and reacted at 50 °C for 24 h. The solvent was then extracted with EA and water, and EA was removed under reduced pressure. Finally, the product was purified by a silica gel column (PE / EA=20:1) to obtain an orange solid, namely CNP2-B.
[0052] Example 2
[0053] The in situ probe gel provided in this embodiment is prepared according to the following method:
[0054] (1) Take 100 mg of hyaluronic acid powder and add it to 20 mL of deionized water, dissolve it with ultrasound assistance, and form a 20 mL uniform solution. Then add 10 mg of dopamine and stir it at room temperature in the dark for 24 hours. Use a 50 mL ultrafiltration centrifuge tube (3Kd), make up the volume with deionized water, repeat centrifugation 5 times to remove unreacted dopamine, obtain a concentrate, and then freeze-dry to obtain HA-DA.
[0055] (2) Dissolve 100 mg HA-DA in 4 mL of PBS solution at pH = 7.4, sonicate and stir to fully dissolve, first add 1 mL of PBS solution of probe HPF (50 μM, DMSO content: 5%) and shake to mix, then add 250 uL of 4.05 mol / L sodium periodate PBS solution, shake to mix, and then stand at room temperature in the dark for 2 hours to obtain the in situ probe gel. The probe HPF can be obtained commercially, for example, it can be purchased from Xi'an Baiying Biotechnology Co., Ltd.
[0056] Test Example 1
[0057] In this test example, nuclear magnetic resonance spectroscopy was used to characterize the HA-DA synthesized in Example 1. Figure 2 The H NMR spectrum of HA-DA in Example 1 is shown. Figure 2 It can be seen that characteristic peaks belonging to hyaluronic acid and dopamine can be detected in the purified HA-DA complex.
[0058] Test Example 2
[0059] In this test example, the morphology of the in situ probe gel of Example 1 was observed and its viscoelasticity was studied.
[0060] like Figure 3 The morphology of the in situ probe gel of Example 1 is shown. Figure 3 It can be seen that the in situ probe gel is brown in color as a whole and has injectable properties.
[0061] like Figure 4 The figure shows the viscoelasticity of the in situ probe gel of Example 1. Figure 4 (a) Schematic diagram of the ductility of the in situ probe gel; Figure 4 (b) is a schematic diagram of the adhesion of the in situ probe gel. Figure 4 It can be seen that the in situ probe gel has excellent ductility and certain adhesion.
[0062] Test Example 3
[0063] In this test example, the in-situ probe gel of Example 1 was observed using a scanning electron microscope and an atomic force microscope.
[0064] like Figure 5A Shown is the SEM image of the in situ probe gel of Example 1. Figure 5B Shown is an AFM image of the in situ probe gel of Example 1. Figure 5A and Figure 5B It can be seen that the interior of the in situ probe gel is loose and porous, which is conducive to the accumulation and sustained release of the probe solution.
[0065] Test Example 4
[0066] This test example characterizes the in situ probe gel delivery molecule of Example 1. The specific steps are: take a piece of fat tissue and apply the in situ probe gel of Example 1 thereon, remove the in situ probe gel by adsorption with filter paper after 10 minutes, and then perform in situ imaging of the fat tissue.
[0067] like Figure 6 The fluorescence imaging diagram of the in situ probe gel delivery probe molecule of Example 1 is shown. Figure 6 It can be seen that the fluorescence signal can be monitored at the controllable coating position of the gel, proving that the in situ probe gel can deliver probe molecules to adipose tissue.
[0068] Test Example 5
[0069] In this test example, the in situ probe gels prepared in Example 1 and Example 2 were used for in situ imaging of mouse carotid atherosclerotic plaques, and the specific steps included:
[0070] After carotid artery ligation, ApoE mice were fed a high-fat diet for 4 weeks to induce the formation of atherosclerotic plaques at specific locations. The carotid artery was surgically exposed, and the in situ probe gel was incubated outside the blood vessel for 10 minutes. The gel was removed with filter paper for in vivo imaging observation.
[0071] like Figure 7 The fluorescence imaging of the in situ probe gel of Example 1 is shown. Figure 7 It can be seen that the use of gel to carry lipid droplets / ONOO - The dual-response fluorescent probe CNP2-B was used for in situ imaging of carotid atherosclerotic plaques in mice, and plaques in the carotid artery vascular area could be clearly observed.
[0072] like Figure 8 The fluorescence imaging of the in situ probe gel of Example 2 is shown. Figure 8 It can be seen that the use of gel to carry ONOO - Asymmetric fluorescence distribution in vascular areas can also be observed in response to the fluorescent probe HPF, proving that the precise delineation of plaque locations requires the cooperation of specific probes.
[0073] The embodiments described above are part of the embodiments of the present invention, rather than all of the embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
Claims
1. A method for preparing an in situ probe gel, characterized in that: The following steps are involved: S1. Add hyaluronic acid powder into deionized water and perform ultrasonic treatment to obtain a uniform solution; S2, after adding dopamine to the homogeneous solution, stirring at room temperature in the dark for 22 to 26 hours, centrifuging and freeze-drying to obtain hyaluronic acid-dopamine; S3, dissolving the hyaluronic acid-dopamine in PBS solution, ultrasonically treating and stirring, adding lipid droplets / ONOO - The PBS solution of the dual-response fluorescent probe CNP2-B is mixed, and then the PBS solution of sodium periodate is added and mixed, and the mixture is allowed to stand at room temperature in the dark for 1.5 to 2.5 hours to obtain an in-situ probe gel; wherein the preparation method of CNP2-B is as follows: 100 mg 0.713 mmol of the compound 4-fluoro-2-hydroxybenzaldehyde and 246.59 mg 1.78 mmol of K2CO3 were added to 20 mL of acetonitrile and stirred for 5 minutes, followed by the addition of 211.97 mg 0.73 mmol of the compound 4-(bromomethyl)phenylboronic acid pinacol ester, followed by stirring for 24 hours overnight, and then the solvent was removed under reduced pressure, and the product was purified using a silica gel column to obtain a light yellow solid, i.e., the intermediate product CN-1; wherein, in the silica gel column, DCM / MeOH=100:1; 100.0 mg 0.280 mmol of the intermediate product CN-1 and 0.5 mL Et3N were added to a mixed solution of EtOH / DCM with a volume ratio of 10 mL:10 mL, and stirred at room temperature for 5 minutes. Then 48.91 mg 0.280 mmol of benzothiazole-2-acetonitrile was added to the reaction solution and reacted at room temperature for 2 h. After removing the solvent under reduced pressure, the product was suspended with 20 mL EA and then filtered to obtain an orange solid, i.e., the intermediate product CN-2; 100.0 mg 0.195 mmol of the intermediate compound CN-2 and 0.5 mL 3,5-dimethylpiperidine were added to 10 mL DMF and reacted at 50° C. for 24 h. The solvent was then extracted with EA and water, and EA was removed under reduced pressure. Finally, the product was purified by a silica gel column to obtain an orange solid, namely CNP2-B, wherein PE / EA in the silica gel column was 20:
1.
2. The preparation method according to claim 1, characterized in that In step S1, the mass volume ratio of the hyaluronic acid powder to deionized water is 4.8-5.2:1 mg / mL.
3. The preparation method according to claim 1, characterized in that: The mass ratio of the hyaluronic acid powder to the dopamine is 9.5-10.5:
1.
4. The preparation method according to claim 1, characterized in that: In step S2, the number of centrifugation is 4 to 6 times.
5. The preparation method according to claim 1, characterized in that In step S3, the mass volume ratio of the hyaluronic acid-dopamine to the PBS solution is 23-27:1 mg / mL.
6. The preparation method according to claim 1, characterized in that: In step S3, the pH value of the PBS solution is 7.35-7.
45.
7. The preparation method according to claim 1, characterized in that In step S3, the mass volume ratio of the hyaluronic acid-dopamine and the PBS solution of the probe is 95-105:1 mg / mL, the PBS solution of the probe also includes dimethyl sulfoxide, the concentration of the probe in the PBS solution of the probe is 48-52 μmol / L, and the mass percentage of the dimethyl sulfoxide is 4.5-5.5%.
8. The preparation method according to claim 1, characterized in that In step S3, the mass volume ratio of the hyaluronic acid-dopamine to the potassium periodate PBS solution is 1:2.3-2.7 mg / mL, and the molar concentration of potassium periodate in the potassium periodate PBS solution is 4-4.1 mol / L.
9. An in situ probe gel, characterized in that: Prepared according to the preparation method according to any one of claims 1 to 8.
